World Workshop on Oral Medicine VI: A systematic review of the treatment of mucocutaneous pemphigus vulgaris

R. McMillan; J. Taylor; M. Shephard; R. Ahmed; M. Carrozzo; J. Setterfield; S. Grando; M. Mignogna; M. Kuten-Shorrer; T. Musbah; A. Elia; R. McGowan; A. R. Kerr; M. S. Greenberg; T. Hodgson; D. Sirois

doi:10.1016/j.oooo.2015.01.022

World Workshop on Oral Medicine VI: A systematic review of the treatment of mucocutaneous pemphigus vulgaris

R. McMillan, J. Taylor, M. Shephard, R. Ahmed, M. Carrozzo, J. Setterfield, S. Grando, M. Mignogna, M. Kuten-Shorrer, T. Musbah, A. Elia, R. McGowan, A. R. Kerr, M. S. Greenberg, T. Hodgson, D. Sirois

Oral Health Practice

Research output: Contribution to journal › Article › peer-review

39 Scopus citations

Abstract

Objective To determine the efficacy and safety of interventions for pemphigus vulgaris (PV). Study Design We conducted a systematic review from 2003 to 2013 according to the Cochrane Collaboration methodology. Randomized controlled trials (RCTs) or controlled clinical trials (CCTs) and observational studies were conducted along with diagnosis confirmed by clinical, histopathologic, and immunofluorescence criteria. Primary outcomes were disease remission and mortality; several relevant secondary outcomes were also included. Results Fourteen RCTs or CCTs and 110 observational studies were included in the final analyses. RCTs or CCTs demonstrated considerable heterogeneity in outcome measures, and all had a high risk of bias for at least 1 of 8 domains. Of the studies, 96.8% (120) described the use of oral corticosteroids. Azathioprine and mycophenolate-mofetil were the most commonly cited treatments. An increasing number of studies described biologic therapies (rituximab, intravenous immunoglobulin [IVIg]). Evidence supporting recent comprehensive treatment guidelines was reviewed. Conclusions We found persisting wide variations in treatment practice and inadequate quality of research supporting optimal PV treatment.

Original language	English
Pages (from-to)	132-142.e61
Journal	Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
Volume	120
Issue number	2
DOIs	https://doi.org/10.1016/j.oooo.2015.01.022
State	Published - 2015

Bibliographical note

Funding Information:
The authors would like to gratefully acknowledge the following organizations, individuals, and companies, which provided unrestricted financial support of WWOM VI: American Academy of Oral Medicine, European Association of Oral Medicine, Anonymous gifts from patients of Dr. David Sirois, New York University College of Dentistry, Biocosmetics, Elsevier, Johnson and Johnson, The Oral Cancer Foundation, and Unilever.

Publisher Copyright:
© 2015 Elsevier Inc.

ASJC Scopus subject areas

Surgery
Oral Surgery
Pathology and Forensic Medicine
Dentistry (miscellaneous)
Radiology Nuclear Medicine and imaging

Access to Document

10.1016/j.oooo.2015.01.022

Cite this

McMillan, R., Taylor, J., Shephard, M., Ahmed, R., Carrozzo, M., Setterfield, J., Grando, S., Mignogna, M., Kuten-Shorrer, M., Musbah, T., Elia, A., McGowan, R., Kerr, A. R., Greenberg, M. S., Hodgson, T., & Sirois, D. (2015). World Workshop on Oral Medicine VI: A systematic review of the treatment of mucocutaneous pemphigus vulgaris. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 120(2), 132-142.e61. https://doi.org/10.1016/j.oooo.2015.01.022

@article{20b55cd03c79442a803e7714e7b0839f,

title = "World Workshop on Oral Medicine VI: A systematic review of the treatment of mucocutaneous pemphigus vulgaris",

abstract = "Objective To determine the efficacy and safety of interventions for pemphigus vulgaris (PV). Study Design We conducted a systematic review from 2003 to 2013 according to the Cochrane Collaboration methodology. Randomized controlled trials (RCTs) or controlled clinical trials (CCTs) and observational studies were conducted along with diagnosis confirmed by clinical, histopathologic, and immunofluorescence criteria. Primary outcomes were disease remission and mortality; several relevant secondary outcomes were also included. Results Fourteen RCTs or CCTs and 110 observational studies were included in the final analyses. RCTs or CCTs demonstrated considerable heterogeneity in outcome measures, and all had a high risk of bias for at least 1 of 8 domains. Of the studies, 96.8% (120) described the use of oral corticosteroids. Azathioprine and mycophenolate-mofetil were the most commonly cited treatments. An increasing number of studies described biologic therapies (rituximab, intravenous immunoglobulin [IVIg]). Evidence supporting recent comprehensive treatment guidelines was reviewed. Conclusions We found persisting wide variations in treatment practice and inadequate quality of research supporting optimal PV treatment.",

author = "R. McMillan and J. Taylor and M. Shephard and R. Ahmed and M. Carrozzo and J. Setterfield and S. Grando and M. Mignogna and M. Kuten-Shorrer and T. Musbah and A. Elia and R. McGowan and Kerr, {A. R.} and Greenberg, {M. S.} and T. Hodgson and D. Sirois",

note = "Funding Information: The authors would like to gratefully acknowledge the following organizations, individuals, and companies, which provided unrestricted financial support of WWOM VI: American Academy of Oral Medicine, European Association of Oral Medicine, Anonymous gifts from patients of Dr. David Sirois, New York University College of Dentistry, Biocosmetics, Elsevier, Johnson and Johnson, The Oral Cancer Foundation, and Unilever. Publisher Copyright: {\textcopyright} 2015 Elsevier Inc.",

year = "2015",

doi = "10.1016/j.oooo.2015.01.022",

language = "English",

volume = "120",

pages = "132--142.e61",

number = "2",

}

McMillan, R, Taylor, J, Shephard, M, Ahmed, R, Carrozzo, M, Setterfield, J, Grando, S, Mignogna, M, Kuten-Shorrer, M, Musbah, T, Elia, A, McGowan, R, Kerr, AR, Greenberg, MS, Hodgson, T & Sirois, D 2015, 'World Workshop on Oral Medicine VI: A systematic review of the treatment of mucocutaneous pemphigus vulgaris', Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, vol. 120, no. 2, pp. 132-142.e61. https://doi.org/10.1016/j.oooo.2015.01.022

TY - JOUR

T1 - World Workshop on Oral Medicine VI

T2 - A systematic review of the treatment of mucocutaneous pemphigus vulgaris

AU - McMillan, R.

AU - Taylor, J.

AU - Shephard, M.

AU - Ahmed, R.

AU - Carrozzo, M.

AU - Setterfield, J.

AU - Grando, S.

AU - Mignogna, M.

AU - Kuten-Shorrer, M.

AU - Musbah, T.

AU - Elia, A.

AU - McGowan, R.

AU - Kerr, A. R.

AU - Greenberg, M. S.

AU - Hodgson, T.

AU - Sirois, D.

N1 - Funding Information: The authors would like to gratefully acknowledge the following organizations, individuals, and companies, which provided unrestricted financial support of WWOM VI: American Academy of Oral Medicine, European Association of Oral Medicine, Anonymous gifts from patients of Dr. David Sirois, New York University College of Dentistry, Biocosmetics, Elsevier, Johnson and Johnson, The Oral Cancer Foundation, and Unilever. Publisher Copyright: © 2015 Elsevier Inc.

PY - 2015

Y1 - 2015

N2 - Objective To determine the efficacy and safety of interventions for pemphigus vulgaris (PV). Study Design We conducted a systematic review from 2003 to 2013 according to the Cochrane Collaboration methodology. Randomized controlled trials (RCTs) or controlled clinical trials (CCTs) and observational studies were conducted along with diagnosis confirmed by clinical, histopathologic, and immunofluorescence criteria. Primary outcomes were disease remission and mortality; several relevant secondary outcomes were also included. Results Fourteen RCTs or CCTs and 110 observational studies were included in the final analyses. RCTs or CCTs demonstrated considerable heterogeneity in outcome measures, and all had a high risk of bias for at least 1 of 8 domains. Of the studies, 96.8% (120) described the use of oral corticosteroids. Azathioprine and mycophenolate-mofetil were the most commonly cited treatments. An increasing number of studies described biologic therapies (rituximab, intravenous immunoglobulin [IVIg]). Evidence supporting recent comprehensive treatment guidelines was reviewed. Conclusions We found persisting wide variations in treatment practice and inadequate quality of research supporting optimal PV treatment.

AB - Objective To determine the efficacy and safety of interventions for pemphigus vulgaris (PV). Study Design We conducted a systematic review from 2003 to 2013 according to the Cochrane Collaboration methodology. Randomized controlled trials (RCTs) or controlled clinical trials (CCTs) and observational studies were conducted along with diagnosis confirmed by clinical, histopathologic, and immunofluorescence criteria. Primary outcomes were disease remission and mortality; several relevant secondary outcomes were also included. Results Fourteen RCTs or CCTs and 110 observational studies were included in the final analyses. RCTs or CCTs demonstrated considerable heterogeneity in outcome measures, and all had a high risk of bias for at least 1 of 8 domains. Of the studies, 96.8% (120) described the use of oral corticosteroids. Azathioprine and mycophenolate-mofetil were the most commonly cited treatments. An increasing number of studies described biologic therapies (rituximab, intravenous immunoglobulin [IVIg]). Evidence supporting recent comprehensive treatment guidelines was reviewed. Conclusions We found persisting wide variations in treatment practice and inadequate quality of research supporting optimal PV treatment.

UR - http://www.scopus.com/inward/record.url?scp=84947041333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947041333&partnerID=8YFLogxK

U2 - 10.1016/j.oooo.2015.01.022

DO - 10.1016/j.oooo.2015.01.022

M3 - Article

C2 - 25934414

AN - SCOPUS:84947041333

VL - 120

SP - 132-142.e61

IS - 2

ER -

World Workshop on Oral Medicine VI: A systematic review of the treatment of mucocutaneous pemphigus vulgaris

Abstract

Bibliographical note

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this